Business Wire

Builder.ai Strengthens Leadership with Craig Saunders from Amazon as New Vice President of Artificial Intelligence

Share

Builder.ai, the AI-powered composable software platform that allows every business and entrepreneur to become digitally powered, is excited to announce the appointment of Craig Saunders as Vice President of Artificial Intelligence. Craig Saunders, a powerhouse in the AI industry, joins Builder.ai from Amazon, where he spent seven transformative years within the Artificial General Intelligence (AGI) organisation.

During his tenure at Amazon, Craig made a significant impact by pioneering technologies for Alexa. He led research and engineering teams building foundational Knowledge Graphs for General Q&A on Alexa, established partnerships with leading universities, and his teams launched challenges within the academic community such as FEVER (Fact Extraction and Verification) to move the state of the art forward on factual accuracy of knowledge graphs. His leadership extended to Natural Language Understanding, including use of seq2seq models in Alexa, and formed the team that federated across multiple Alexa Q&A systems. In 2022, Craig led teams that were building the next generation of textual Large Language Models for Amazon, and advanced personalisation for Alexa.

“Craig’s remarkable achievements in AI - and his visionary approach to multi disciplinary, multi modal AI will enable us to propel Natasha and our AI capabilities to newer frontiers and allow us to drive an even richer customer experience,” said Sachin Dev Duggal, Founder & Chief Wizard, Builder.ai. “His expertise is not just in technology, but in fostering scaled innovation that resonates with customers on a global scale. I’m thrilled to have Craig join the team and excited to see what he and the team add to the Platform and Natasha’s capabilities.”

In his new role, Saunders will lead the AI teams at Builder.ai, focusing on scaling and expanding the company's existing AI capabilities, including Natasha, the world’s first AI product manager, and its new Code Generation System, which automates the transition from a user conversation directly to working code. His expertise will be instrumental in propelling Builder.ai to deliver even more for their customers through tailored software solutions with unprecedented efficiency.

“Joining Builder.ai feels like a natural progression in my career, allowing me to further push the boundaries of AI and machine learning solutions,” adds Craig Saunders. “I’m excited to be a part of the development of cutting-edge AI solutions that will not only transform the way software is created but also empower our customers to achieve their ambitious business goals.”

Craig received a PhD in Machine Learning from the University of London in 2000 and continued in the education sector, working nine years as an academic faculty at Royal Holloway, University of London and the University of Southampton. Utilising his expertise and knowledge, he transitioned to a career at Xerox where he delivered machine learning solutions across diverse industries including transportation, healthcare, and finance. Additionally, Craig has successfully published over 70 academic papers in leading conferences and journals, and holds several patents.

Established in 2016, Builder.ai leads the industry with its AI-powered composable software platform, allowing anyone with an idea to develop an app (web or mobile) more quickly and affordably. By decomposing software into reusable Lego-like features and combining them with cutting-edge AI and a patented software assembly line, Builder.ai has demonstrated global success in enabling customers of all sizes to adopt a software-first approach.

About Builder.ai

Builder.ai® is an AI-powered composable software platform for every idea and company globally. The AI-powered assembly line integrates Lego-like reusable features with Building Blocks™ automation to minimise human effort, leverages a verified network of experts to significantly extend development capabilities, and produces apps with a nearly zero failure rate at a fraction of the cost and time of traditional software development.

Led by serial entrepreneur Sachin Dev Duggal, Builder.ai is reshaping the construction and operation of software with a suite of products and services, including BUILDER STUDIO, BUILDER CLOUD, BUILDER NOW, and STUDIO STORE. Builder.ai was featured on the 2023 Fast Company list of Most Innovative Companies, received the “Hottest AI Startup” and 2022’s “Hottest Scale-Up” awards at the Europas for Europe's successful tech startups, and won the Best COVID-19 Innovation for Recovery at CogX. It was also named 'Visionary' in the 2021 Gartner® Magic Quadrant™ for Multi-experience Development Platforms. Builder.ai is headquartered in London, with employees and hubs in Delhi NCR, Singapore, Los Angeles, Salt Lake City, Sophia Antipolis, and Dubai. For more information, visit Builder.ai.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240611122778/en/

Contacts

Stephanie.lowenthal@builder.ai

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 10:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap

DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 09:30:00 EET | Press release

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical

Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 04:41:00 EET | Press release

Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm

Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 03:15:00 EET | Press release

Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly three years, while adding a seasoned in-country team spanning operations, support, sales, finance, and leadership to enable rapid integration and future growth. The E

IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 23:10:00 EET | Press release

IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerstone of IonQ’s global strategy,” said Niccolo de Masi, Chairman and CEO of IonQ. “QuantumBasel continues to be a critical innovation node for our company as

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye